Voyager Therapeutics, Inc. (VYGR) Spending and interest coverage
- R&D / revenue · 12 months: Value 343.77%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 34.54%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 343.77% | Research and development expense / revenue. Period ending 2026-06-30. $118.46M ÷ $34.46M × 100 ≈ 343.77% |
| Stock-based compensation / revenue · 12 months | 34.54% | Share-based compensation / revenue. Period ending 2026-06-30. $11.90M ÷ $34.46M × 100 ≈ 34.54% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 118.46M USD | Research and Development Expense |
| Revenue | 34.46M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 11.90M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -117.19M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $118.46M | $34.46M | $11.90M | $-117.19M | (m) | 343.77% | 34.54% | (m) | (m) |
| 2026-03-31 | $127.75M | $36.49M | $13.60M | $-127.42M | (m) | 350.06% | 37.27% | (m) | (m) |
| 2025-12-31 | $134.67M | $40.37M | $14.79M | $-131.84M | (m) | 333.57% | 36.63% | (m) | (m) |
| 2025-09-30 | $134.31M | $31.32M | $15.00M | $-140.21M | (m) | 428.87% | 47.91% | (m) | (m) |
| 2025-06-30 | $128.68M | $42.58M | $14.98M | $-123.40M | (m) | 302.21% | 35.17% | (m) | (m) |
| 2025-03-31 | $131.80M | $66.96M | $14.88M | $-101.80M | (m) | 196.84% | 22.23% | (m) | (m) |
| 2024-12-31 | $127.37M | $80.00M | $14.79M | $-83.29M | (m) | 159.21% | 18.48% | (m) | (m) |
| 2024-09-30 | $117.54M | $64.28M | $14.09M | $9.07M | (m) | 182.87% | 21.93% | (m) | (m) |
| 2024-06-30 | $113.16M | $44.26M | $13.54M | $-6.65M | (m) | 255.67% | 30.59% | (m) | (m) |
| 2024-03-31 | $100.70M | $19.54M | $12.17M | $-17.05M | (m) | 515.44% | 62.29% | (m) | (m) |
| 2023-12-31 | $92.17M | $250.01M | $11.15M | $122.01M | (m) | 36.87% | 4.46% | (m) | (m) |
| 2023-09-30 | $80.97M | $158.40M | $10.45M | $43.39M | (m) | 51.12% | 6.60% | (m) | (m) |
| 2023-06-30 | $74.44M | $194.87M | $9.77M | $87.34M | (m) | 38.20% | 5.01% | (m) | (m) |
| 2023-03-31 | $64.98M | $190.73M | $9.58M | $93.40M | (m) | 34.07% | 5.02% | (m) | (m) |
| 2022-12-31 | $60.76M | $40.91M | $9.34M | $-50.84M | (m) | 148.54% | 22.84% | (m) | (m) |
| 2022-09-30 | $60.23M | $70.53M | $8.65M | $-20.57M | (m) | 85.40% | 12.27% | (m) | (m) |
| 2022-06-30 | $58.81M | $30.93M | $8.54M | $-60.16M | (m) | 190.16% | 27.62% | (m) | (m) |
| 2022-03-31 | $65.79M | $31.57M | $10.04M | $-69.38M | (m) | 208.38% | 31.81% | (m) | (m) |
| 2021-12-31 | $73.79M | $37.41M | $11.32M | $-73.62M | (m) | 197.21% | 30.27% | (m) | (m) |
| 2021-09-30 | $81.76M | $15.88M | $13.17M | $-103.05M | (m) | 514.91% | 82.95% | (m) | (m) |
| 2021-06-30 | $88.89M | $132.24M | $14.63M | $6.62M | (m) | 67.22% | 11.06% | (m) | (m) |
| 2021-03-31 | $98.81M | $159.56M | $14.49M | $26.23M | (m) | 61.92% | 9.08% | (m) | (m) |
| 2020-12-31 | $108.75M | $171.13M | $14.93M | $27.38M | (m) | 63.55% | 8.73% | (m) | (m) |
| 2020-09-30 | $123.31M | $197.26M | $14.95M | $37.34M | (m) | 62.51% | 7.58% | (m) | (m) |
| 2020-06-30 | $128.05M | $99.86M | $14.77M | $-64.99M | (m) | 128.23% | 14.79% | (m) | (m) |
| 2020-03-31 | $127.20M | $117.26M | $16.16M | $-46.82M | (m) | 108.47% | 13.78% | (m) | (m) |
| 2019-12-31 | $119.73M | $104.39M | $15.64M | $-51.68M | (m) | 114.70% | 14.98% | (m) | (m) |
| 2019-09-30 | $100.10M | $73.72M | $14.76M | $-61.07M | (m) | 135.77% | 20.02% | (m) | (m) |
| 2019-06-30 | $86.95M | $55.39M | $14.04M | $-64.41M | (m) | 156.99% | 25.36% | (m) | (m) |
| 2019-03-31 | $74.88M | $11.87M | $16.91M | $-99.30M | (m) | 630.65% | 142.38% | (m) | (m) |
| 2018-12-31 | $64.91M | $7.62M | $15.71M | $-91.09M | (m) | 851.88% | 206.20% | (m) | (m) |
| 2018-09-30 | $61.32M | $11.96M | $15.37M | $-80.28M | (m) | 512.86% | 128.51% | (m) | (m) |
| 2018-06-30 | $64.25M | $11.01M | $15.97M | $-82.49M | (m) | 583.54% | 145.05% | (m) | (m) |
| 2018-03-31 | $63.04M | $9.61M | $9.39M | $-75.43M | (m) | 655.79% | 97.73% | (m) | (m) |
| 2017-12-31 | $62.26M | $10.13M | $9.24M | $-71.86M | (m) | 614.31% | 91.15% | (m) | (m) |
| 2017-09-30 | $61.66M | $6.15M | $8.73M | $-73.36M | (m) | 1002.21% | 141.86% | (m) | (m) |
| 2017-06-30 | $52.41M | $8.31M | $7.28M | $-60.37M | (m) | 630.47% | 87.52% | (m) | (m) |
| 2017-03-31 | $47.59M | $10.85M | $7.05M | $-51.35M | (m) | 438.45% | 64.98% | (m) | (m) |
| 2016-12-31 | $42.25M | $14.22M | $6.31M | $-41.30M | (m) | 297.11% | 44.37% | (m) | (m) |
| 2016-09-30 | $38.75M | $16.80M | $6.49M | $-34.90M | (m) | 230.70% | 38.67% | (m) | (m) |
| 2016-06-30 | $34.92M | $18.42M | $5.56M | $-28.54M | (m) | 189.52% | 30.19% | (m) | (m) |
| 2016-03-31 | $30.89M | $19.59M | $5.15M | $-22.89M | (m) | 157.69% | 26.28% | (m) | (m) |
| 2015-12-31 | $27.68M | $17.33M | $4.03M | $-20.25M | (m) | 159.68% | 23.23% | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | $-16.95M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | $-16.21M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $8.90M | (m) | $425.00K | $-14.37M | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |